Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Director Robert Mittendorff reported purchasing 1,333,333 shares of Carlmed, Inc. (NASDAQ:CARL) common stock at a price of $15.0 per share, for a total transaction value of $19,999,995. The purchase price sits near the stock’s 52-week high of $15.2, with the company currently valued at $384.49 million. According to InvestingPro analysis, Carlmed appears overvalued at current levels.
On July 24, 2025, Mittendorff acquired the shares. The transactions also involved the conversion of Series B and Series C Preferred Stock into common stock. These conversions involved B Capital Global Growth III, L.P., B Capital Healthcare I, L.P., and Hornet Co-Invest, L.P. into an aggregate of 7,925,952 shares of common stock. While the company maintains strong liquidity with a current ratio of 6.48, InvestingPro data shows it isn’t currently profitable, with additional financial insights available to subscribers.
Following these transactions, Mittendorff now indirectly owns 5,013,839 shares of Carlmed, Inc. common stock. The company operates with moderate debt levels and maintains substantial liquid assets exceeding short-term obligations, according to InvestingPro analysis.
In other recent news, Carlsmed , Inc. has successfully launched its initial public offering, pricing its shares at $15.00 each. The company offered 6,700,000 shares of common stock, and trading commenced on the Nasdaq Global Select Market under the symbol "CARL." This IPO is projected to generate approximately $100.5 million in gross proceeds before accounting for underwriting discounts, commissions, and other expenses. Notably, underwriters have a 30-day option to purchase up to an additional 1,005,000 shares at the initial offering price. The offering is expected to close soon, pending customary closing conditions. These developments mark a significant milestone for Carlsmed as it enters the public market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.